New insights into the epidemiology of gout
- PMID: 19447779
- DOI: 10.1093/rheumatology/kep086
New insights into the epidemiology of gout
Abstract
Gout is a true crystal deposition disease caused by formation of monosodium urate crystals in joints and other tissues. It is a common inflammatory arthritis that has increased in prevalence in recent decades. Gout normally results from the interaction of genetic, constitutional and environmental risk factors. It is more common in men and strongly age related. A major determinant is the degree of elevation of uric acid levels above the saturation point for urate crystal formation, principally caused by inefficient renal urate excretion. Local joint tissue factors may influence the topography and extent of crystal deposition. Recent studies have provided information on dietary risk factors for gout: higher intakes of red meat, fructose and beer are independently associated with increased risk, whereas higher intakes of coffee, low-fat dairy products and vitamin C are associated with lower risk. Several renal urate transporters have been identified including URAT1 and SLC2A9 (GLUT9) and polymorphisms in these genes are associated with an increased risk of hyperuricaemia and gout. Many drugs influence serum uric acid levels through an effect on renal urate transport. Comorbidities, including the metabolic syndrome and impaired renal function are common in gout patients. The usual initial presentation of gout is with rapidly developing acute inflammatory monoarthritis, typically affecting the first MTP joint. If left untreated it may progress with recurrent acute attacks and eventual development of chronic symptoms and joint damage. New knowledge of the modifiable risk factors for gout can be integrated into the management strategy to optimize long-term patient outcomes.
Comment in
-
Comment on: new insights into the epidemiology of gout.Rheumatology (Oxford). 2010 Mar;49(3):613-4; author reply 614. doi: 10.1093/rheumatology/kep349. Epub 2009 Nov 11. Rheumatology (Oxford). 2010. PMID: 19906832 No abstract available.
Similar articles
-
Gout: epitome of painful arthritis.Metabolism. 2010 Oct;59 Suppl 1:S32-6. doi: 10.1016/j.metabol.2010.07.009. Metabolism. 2010. PMID: 20837191 Review.
-
Gout: an update.Am Fam Physician. 2007 Sep 15;76(6):801-8. Am Fam Physician. 2007. PMID: 17910294 Review.
-
What do I need to know about gout?J Fam Pract. 2010 Jun;59(6 Suppl):S1-8. J Fam Pract. 2010. PMID: 20544070 Review.
-
Pathogenesis, clinical findings and management of acute and chronic gout.Minerva Med. 2006 Dec;97(6):495-509. Minerva Med. 2006. PMID: 17213786 Review.
-
Clinical features of gout.Reumatismo. 2012 Jan 19;63(4):238-45. doi: 10.4081/reumatismo.2011.238. Reumatismo. 2012. PMID: 22303530 Review.
Cited by
-
New and improved strategies for the treatment of gout.Int J Nephrol Renovasc Dis. 2010;3:145-66. doi: 10.2147/IJNRD.S6048. Epub 2010 Nov 24. Int J Nephrol Renovasc Dis. 2010. PMID: 21694941 Free PMC article.
-
Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study.Int J Rheumatol. 2014;2014:123105. doi: 10.1155/2014/123105. Epub 2014 Sep 3. Int J Rheumatol. 2014. PMID: 25276138 Free PMC article.
-
Pegloticase for treatment of tophaceous polyarticular gout.Hawaii J Med Public Health. 2013 Jul;72(7):220-3. Hawaii J Med Public Health. 2013. PMID: 23901393 Free PMC article.
-
Oral colchicine (colcrys®) in the treatment and prophylaxis of gout†: profile report.Drugs Aging. 2010 Oct 1;27(10):855-7. doi: 10.2165/11206330-000000000-00000. Drugs Aging. 2010. PMID: 20883065 No abstract available.
-
Correlation between Gout and Coronary Heart Disease in Taiwan: A Nationwide Population-Based Cohort Study.Acta Cardiol Sin. 2019 Nov;35(6):634-640. doi: 10.6515/ACS.201911_35(6).20190403B. Acta Cardiol Sin. 2019. PMID: 31879516 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical